

2023 - 1

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Singh Dave¹²³, Boguş Maxim⁴, Moskalenko Valentyn⁵, Noi Autori

¹ University of Manchester,

² Kyiv City Oleksandrivska Clinical Hospital,

³ Brovary multidisciplinary clinical hospital,

⁴ Timofei Moşneaga Republican Clinical Hospital,

⁵ Kyiv City Clinical Hospital #12

European Respiratory Journal

Vol. 58, / 2021 / ISSN 0903-1936 / ISSN 1399-3003

Disponibil online 19 July, 2023. Descarcări-0. Vizualizări-180

2021 - 1

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

Belperio John A.¹, Nguyen Tuan², Lombardi David A.², Boguş Maxim³⁴, Moskalenko Valentyn⁵⁶, Singh Dave⁷, Haumann Brett⁸, Bourdet David L.², Kaufman Elad², Pfeifer Nathan D.², Thompson Corbin G.², Woo Jacky², Moran Edmund J.², Saggar Rajeev²

¹ Ronald Reagan UCLA Medical Center, Los Angeles,

² Theravance Biopharma Inc, South San Francisco,

³ F.C.E. ARENSIA Exploratory Medicine,

⁴ Timofei Moşneaga Republican Clinical Hospital,

⁵ Kyiv City Clinical Hospital #12,

⁶ Brovary multidisciplinary clinical hospital,

⁷ University of Manchester,

⁸ Theravance Biopharma UK Limited, London

BMJ Open Respiratory Research

Vol. 10, / 2023 / ISSN 2052-4439

Disponibil online 15 August, 2023. Descarcări-1. Vizualizări-140
